BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clark IA. Randomized controlled trial validating the use of perispinal etanercept to reduce post-stroke disability has wide-ranging implications. Expert Rev Neurother 2020;20:203-5. [PMID: 32028804 DOI: 10.1080/14737175.2020.1727742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Clark IA. Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic. Pharmacol Res Perspect 2022;10:e00926. [PMID: 35174650 DOI: 10.1002/prp2.926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Clark IA. How diseases caused by parasites allowed a wider understanding of disease in general: my encounters with parasitology in Australia and elsewhere over the last 50 years. Int J Parasitol 2021:S0020-7519(21)00298-8. [PMID: 34757090 DOI: 10.1016/j.ijpara.2021.10.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Clark IA, Vissel B. Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches. J Alzheimers Dis 2021;79:931-48. [PMID: 33459706 DOI: 10.3233/JAD-201186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
4 Clark IA. Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm. Rev Med Virol 2021;31:1-13. [PMID: 33580566 DOI: 10.1002/rmv.2210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]